Page last updated: 2024-08-24

bmy 25067 and Hematologic Diseases

bmy 25067 has been researched along with Hematologic Diseases in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
de Boer-Dennert, M; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; Verweij, J; Winograd, B	1

Trials

1 trial(s) available for bmy 25067 and Hematologic Diseases

Article	Year
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. Anti-cancer drugs, 1999, Volume: 10, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Neoplasms; Vascular Diseases	1999

Article

Year

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

Anti-cancer drugs, 1999, Volume: 10, Issue:9

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Neoplasms; Vascular Diseases

1999